[{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Montreal Health Innovations Coordinating Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dalcetrapib","moa":"Cholesteryl ester transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"DalCor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DalCor Pharmaceuticals \/ Montreal Health Innovations Coordinating Center","highestDevelopmentStatusID":"10","companyTruncated":"DalCor Pharmaceuticals \/ Montreal Health Innovations Coordinating Center"},{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dalcetrapib","moa":"Cholesteryl ester transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"DalCor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DalCor Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DalCor Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dalcetrapib","moa":"Cholesteryl ester transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"DalCor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DalCor Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DalCor Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Qu\u00e9bec Government","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Series D Financing","leadProduct":"Dalcetrapib","moa":"Cholesteryl ester transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"DalCor Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"DalCor Pharmaceuticals \/ Qu\u00e9bec Government","highestDevelopmentStatusID":"10","companyTruncated":"DalCor Pharmaceuticals \/ Qu\u00e9bec Government"},{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Montreal Health Innovations Coordinating Center | Covance","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dalcetrapib","moa":"Cholesteryl ester transfer protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"DalCor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"DalCor Pharmaceuticals \/ Montreal Health Innovations Coordinating Center | Covance","highestDevelopmentStatusID":"8","companyTruncated":"DalCor Pharmaceuticals \/ Montreal Health Innovations Coordinating Center | Covance"}]